AN2 Therapeutics appoints Joshua Eizen as Chief Legal Officer and COO

AN2 Therapeutics, Inc.

Joshua Eizen appointed Chief Legal Officer and Chief Operating Officer effective Nov 4, 2024.
Salary increased to $450,000; granted option for 63,000 shares and 31,500 RSUs.
Option vests monthly over 48 months; RSUs vest annually over 4 years.
Eizen previously served as Chief Legal Counsel; no family relationships or related-party transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Joshua Eizen

Chief Legal Officer and Chief Operating Officer

ANTX · AN2 Therapeutics, Inc.

Effective: 2024-11-04
Filed: November 5, 2024, 6:59 PM ET

On November 4, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) appointed Joshua Eizen, the Company’s current Chief Legal Counsel, age 47, as Chief Legal Officer and Chief Operating Officer of the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Eizen was appointed as Chief Legal Officer and Chief Operating Officer at AN2 Therapeutics, Inc..

Action: appointed
Role: Chief Legal Officer and Chief Operating Officer

Exact text from the filing

On November 4, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) appointed Joshua Eizen, the Company’s current Chief Legal Counsel, age 47, as Chief Legal Officer and Chief Operating Officer of the Company, effective immediately

View on SEC.gov

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-251240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.